{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:54:55Z","timestamp":1792806895260,"version":"4.5.0"},"reference-count":75,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 GM126833 to GB and BST"],"award-info":[{"award-number":["R01 GM126833 to GB and BST"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Ministry of Education in Taiwan and the Ministry of Science and Technology, Taiwan","award":["MOST 108-3017-F-182-001 to SRS"],"award-info":[{"award-number":["MOST 108-3017-F-182-001 to SRS"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines.<\/jats:p>","DOI":"10.3390\/vaccines9030199","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T20:55:44Z","timestamp":1614459344000},"page":"199","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Enterovirus A71 Vaccines"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6172-5521","authenticated-orcid":false,"given":"Mei-Ling","family":"Li","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Ru","family":"Shih","sequence":"additional","affiliation":[{"name":"Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan"},{"name":"Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Research Center for Chinese Herbal Medicine, Research Center for Food and Cosmetic Safety, and Graduate Institute of Health Industry Technology, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanton S.","family":"Tolbert","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4180-3964","authenticated-orcid":false,"given":"Gary","family":"Brewer","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/infdis\/169.4.905","article-title":"Enterovirus 71 infections and neurologic disease--United States, 1977\u20131991","volume":"169","author":"Alexander","year":"1994","journal-title":"J. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S1474-4422(10)70209-X","article-title":"Clinical features, diagnosis, and management of enterovirus 71","volume":"9","author":"Ooi","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3345\/kjp.2016.59.10.395","article-title":"Enterovirus 71 infection and neurological complications","volume":"59","author":"Lee","year":"2016","journal-title":"Korean J. Pediat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12929-019-0552-7","article-title":"Enterovirus A71 neurologic complications and long-term sequelae","volume":"26","author":"Chang","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12929-019-0573-2","article-title":"The History of Enterovirus A71 Outbreaks and Molecular Epidemiology in the Asia-Pacific Region","volume":"26","author":"Puenpa","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"ref_6","first-page":"1615","article-title":"Enteroviruses: Classification, Diseases They Cause, and Approaches to Development of Antiviral Drugs","volume":"82","author":"Nikonov","year":"2017","journal-title":"Biochemistry."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1517\/14712598.2014.935330","article-title":"Update on the development of enterovirus 71 vaccines","volume":"14","author":"Kung","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1590\/s1678-9946201860070","article-title":"Hand, foot and mouth disease and herpangina caused by enterovirus A71 infections: A review of enterovirus A71 molecular epidemiology, pathogenesis, and current vaccine development","volume":"60","author":"Chang","year":"2018","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fmicb.2020.00261","article-title":"Enterovirus and Encephalitis","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12929-019-0560-7","article-title":"Antivirals and vaccines for Enterovirus A71","volume":"26","author":"Lin","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9658","DOI":"10.1128\/JVI.05063-11","article-title":"Host factors in enterovirus 71 replication","volume":"85","author":"Shih","year":"2011","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/21645515.2019.1581539","article-title":"Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China","volume":"15","author":"Wang","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrmicro906","article-title":"Polio eradication, cessation of vaccination and re-emergence of disease","volume":"2","author":"Minor","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/14760584.2016.1191357","article-title":"Enterovirus 71: A whole virion inactivated enterovirus 71 vaccine","volume":"15","author":"Zhou","year":"2016","journal-title":"Expert Rev. Vaccin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1586\/14760584.2016.1138862","article-title":"EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD)","volume":"15","author":"Mao","year":"2016","journal-title":"Expert Rev. Vaccin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1016\/j.vaccine.2011.04.070","article-title":"Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection","volume":"29","author":"Bek","year":"2011","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1016\/j.vaccine.2011.06.044","article-title":"Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys","volume":"29","author":"Dong","year":"2011","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/cid\/ciu852","article-title":"Review of enterovirus 71 vaccines","volume":"60","author":"Chong","year":"2015","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9668","DOI":"10.1016\/j.vaccine.2011.10.018","article-title":"Establishing China\u2019s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines","volume":"29","author":"Liang","year":"2011","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1303224","article-title":"An inactivated enterovirus 71 vaccine in healthy children","volume":"370","author":"Li","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(13)61049-1","article-title":"Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"381","author":"Zhu","year":"2013","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/infdis\/jiw502","article-title":"2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study","volume":"215","author":"Wei","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/21645515.2018.1442997","article-title":"Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation","volume":"14","author":"Hu","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1016\/j.vaccine.2020.05.001","article-title":"WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines","volume":"38","author":"Lei","year":"2020","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.vaccine.2011.11.087","article-title":"Selection and characterization of vaccine strain for Enterovirus 71 vaccine development","volume":"30","author":"Chang","year":"2012","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.4161\/hv.21739","article-title":"Production of EV71 vaccine candidates","volume":"8","author":"Chong","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.vaccine.2013.03.015","article-title":"A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine","volume":"31","author":"Cheng","year":"2013","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Chou, A.H., Liu, C.C., Chang, C.P., Guo, M.S., Hsieh, S.Y., Yang, W.H., Chao, H.J., Wu, C.L., Huang, J.L., and Lee, M.S. (2012). Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0034834"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chou, A.H., Liu, C.C., Chang, J.Y., Jiang, R., Hsieh, Y.C., Tsao, A., Wu, C.L., Huang, J.L., Fung, C.P., and Hsieh, S.M. (2013). Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079783"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.vaccine.2019.02.023","article-title":"Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan","volume":"37","author":"Huang","year":"2019","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"In, H.J., Lim, H., Lee, J.A., Kim, H.J., Kim, J.W., Hyeon, J.Y., Yeo, S.G., Lee, J.W., Yoo, J.S., and Choi, Y.K. (2017). An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0178259"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12929-019-0574-1","article-title":"Enterovirus A71: Virulence, antigenicity, and genetic evolution over the years","volume":"26","author":"Huang","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Fujii, K., Sudaka, Y., Takashino, A., Kobayashi, K., Kataoka, C., Suzuki, T., Iwata-Yoshikawa, N., Kotani, O., Ami, Y., and Shimizu, H. (2018). VP1 Amino Acid Residue 145 of Enterovirus 71 Is a Key Residue for Its Receptor Attachment and Resistance to Neutralizing Antibody during Cynomolgus Monkey Infection. J. Virol., 92.","DOI":"10.1128\/JVI.00682-18"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Nishimura, Y., Lee, H., Hafenstein, S., Kataoka, C., Wakita, T., Bergelson, J.M., and Shimizu, H. (2013). Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003511"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Yeh, M.T., Wang, S.W., Yu, C.K., Lin, K.H., Lei, H.Y., Su, I.J., and Wang, J.R. (2011). A single nucleotide in stem loop II of 5\u2019-untranslated region contributes to virulence of enterovirus 71 in mice. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027082"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1038\/s41598-018-25091-7","article-title":"Mutations in VP1 and 5\u2032-UTR affect enterovirus 71 virulence","volume":"8","author":"Chang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9386","DOI":"10.1128\/JVI.02856-06","article-title":"An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys","volume":"81","author":"Arita","year":"2007","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1128\/JVI.02139-12","article-title":"Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture","volume":"87","author":"Sadeghipour","year":"2013","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1128\/JVI.00289-14","article-title":"Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice","volume":"88","author":"Meng","year":"2014","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e02308-18","DOI":"10.1128\/JVI.02308-18","article-title":"Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate","volume":"93","author":"Tsai","year":"2019","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1038\/s41598-019-41285-z","article-title":"Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice","volume":"9","author":"Yee","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zhao, D., Sun, B., Sun, S., Fu, B., Liu, C., Liu, D., Chu, Y., Ma, Y., Bai, L., and Wu, Y. (2017). Characterization of human enterovirus71 virus-like particles used for vaccine antigens. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181182"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Qian, C., Liu, X., Xu, Q., Wang, Z., Chen, J., Li, T., Zheng, Q., Yu, H., Gu, Y., and Li, S. (2020). Recent Progress on the Versatility of Virus-Like Particles. Vaccines (Basel), 8.","DOI":"10.3390\/vaccines8010139"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3748\/wjg.v12.i6.921","article-title":"Expression, purification and characterization of enterovirus-71 virus-like particles","volume":"12","author":"Chung","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1023\/A:1024071514438","article-title":"Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells","volume":"25","author":"Hu","year":"2003","journal-title":"Biotechnol. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.vaccine.2011.12.081","article-title":"Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles","volume":"30","author":"Lin","year":"2012","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1126\/science.291.5512.2370","article-title":"Glycosylation and the immune system","volume":"291","author":"Rudd","year":"2001","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11312","DOI":"10.1128\/JVI.01123-15","article-title":"Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity","volume":"89","author":"Hyakumura","year":"2015","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.vaccine.2015.03.034","article-title":"High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice","volume":"33","author":"Zhang","year":"2015","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1016\/j.vaccine.2013.05.019","article-title":"Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice","volume":"31","author":"Li","year":"2013","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Tsou, Y.L., Lin, Y.W., Shao, H.Y., Yu, S.L., Wu, S.R., Lin, H.Y., Liu, C.C., Huang, C., Chong, P., and Chow, Y.H. (2015). Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003692"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1016\/j.vaccine.2016.06.058","article-title":"Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges","volume":"34","author":"Yan","year":"2016","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.clindermatol.2014.12.011","article-title":"Update on hand-foot-and-mouth disease","volume":"33","author":"Ventarola","year":"2015","journal-title":"Clin. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41426-018-0094-1","article-title":"A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity","volume":"7","author":"Zhang","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0264-410X(01)00385-1","article-title":"Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus","volume":"20","author":"Wu","year":"2001","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/jmv.24018","article-title":"Characterization of the enterovirus 71 VP1 protein as a vaccine candidate","volume":"87","author":"Zhou","year":"2015","journal-title":"J. Med. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Meng, T., Kolpe, A.B., Kiener, T.K., Chow, V.T., and Kwang, J. (2011). Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021757"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00705-018-3797-7","article-title":"Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71","volume":"163","author":"Wang","year":"2018","journal-title":"Arch. Virol"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.4161\/hv.29123","article-title":"Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine","volume":"10","author":"Han","year":"2014","journal-title":"Hum. Vaccin. Immunother"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"12088","DOI":"10.1128\/JVI.75.24.12088-12097.2001","article-title":"Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites","volume":"75","author":"Fournillier","year":"2001","journal-title":"J. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1128\/JVI.76.11.5357-5368.2002","article-title":"Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization","volume":"76","author":"Chakrabarti","year":"2002","journal-title":"J. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.virusres.2006.12.005","article-title":"Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides","volume":"125","author":"Foo","year":"2007","journal-title":"Virus Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.micinf.2007.06.002","article-title":"Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide","volume":"9","author":"Foo","year":"2007","journal-title":"Microbes. Infect."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1016\/j.vaccine.2010.08.080","article-title":"Combined peptides of human enterovirus 71 protect against virus infection in mice","volume":"28","author":"Liu","year":"2010","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Aw-Yong, K.L., Sam, I.C., Koh, M.T., and Chan, Y.F. (2016). Immunodominant IgM and IgG Epitopes Recognized by Antibodies Induced in Enterovirus A71-Associated Hand, Foot and Mouth Disease Patients. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165659"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7150\/thno.7457","article-title":"Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop","volume":"4","author":"Xu","year":"2014","journal-title":"Theranostics"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1016\/j.vaccine.2017.10.101","article-title":"Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice","volume":"35","author":"Huo","year":"2017","journal-title":"Vaccine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1016\/j.vaccine.2015.10.104","article-title":"A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice","volume":"33","author":"Jiang","year":"2015","journal-title":"Vaccine"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Mustafa, S., Abd-Aziz, N., Saw, W.T., Liew, S.Y., Yusoff, K., and Shafee, N. (2020). Recombinant Enterovirus 71 Viral Protein 1 Fused to a Truncated Newcastle Disease Virus NP (NPt) Carrier Protein. Vaccines (Basel), 8.","DOI":"10.3390\/vaccines8040742"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1743-422X-8-106","article-title":"Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo","volume":"8","author":"Han","year":"2011","journal-title":"Virol. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nsmb.2255","article-title":"A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71","volume":"19","author":"Wang","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Widge, A.T., Rouphael, N.G., Jackson, L.A., Anderson, E.J., Roberts, P.C., Makhene, M., Chappell, J.D., Denison, M.R., Stevens, L.J., and Pruijssers, A.J. (2020). Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N. Engl. J. Med.","DOI":"10.1056\/NEJMc2032195"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/3\/199\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:30:02Z","timestamp":1760160602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/3\/199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":75,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["vaccines9030199"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9030199","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]}}}